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Summary The G1 restriction point is critical for regulating
the cell cycle and is controlled by the Rb pathway (CDK4/6-
cyclin D1-Rb-p16/ink4a). This pathway is important because
of its inactivation in a majority of human tumors. Transition
through the restriction point requires phosphorylation of reti-
noblastoma protein (Rb) by CDK4/6, which are highly vali-
dated cancer drug targets. We present the identification and
characterization of a potent CDK4/6 inhibitor, LY2835219.
LY2835219 inhibits CDK4 and CDK6 with low nanomolar
potency, inhibits Rb phosphorylation resulting in a G1 arrest
and inhibition of proliferation, and its activity is specific for
Rb-proficient cells. In vivo target inhibition studies show
LY2835219 is a potent inhibitor of Rb phosphorylation,
induces a complete cell cycle arrest and suppresses expression
of several Rb-E2F-regulated proteins 24 hours after a single
dose. Oral administration of LY2835219 inhibits tumor
growth in human tumor xenografts representing different his-
tologies in tumor-bearing mice. LY2835219 is effective and
well tolerated when administered up to 56 days in immuno-
deficient mice without significant loss of body weight or
tumor outgrowth. In calu-6 xenografts, LY2835219 in com-
bination with gemcitabine enhanced in vivo antitumor activity
without a G1 cell cycle arrest, but was associated with a
reduction of ribonucleotide reductase expression. These re-
sults suggest LY2835219 may be used alone or in combina-
tion with standard-of-care cytotoxic therapy. In summary, we
have identified a potent, orally active small-molecule inhibitor
of CDK4/6 that is active in xenograft tumors. LY2835219 is
currently in clinical development.
Keywords CDK4/6 inhibitor . Cell cycle . LY2835219 .
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Introduction
Sustained proliferative capacity is a hallmark of cancer [1].
The cell cycle is the process by which mammalian cells
regulate proliferation and has 4 functional phases: S phase
when DNA replication occurs; M phase (mitosis): when
DNA and cellular components are divided to form 2 daughter
cells; the G2 phase between S and M when cells prepare for
mitosis; and the G1 phase after mitosis and before phase S
when cells commit and prepare for another round of DNA and
cellular replication. The G1 restriction point (R) was
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originally described as the point where cell proliferation be-
comes independent of mitogens and growth factors [2], and
the normal function of the restriction point is essential for
maintaining control of cellular proliferation [3, 4]. The restric-
tion point is controlled by the retinoblastoma pathway
(CDK4/6-cyclin D1-Rb-p16/ink4a). The retinoblastoma pro-
tein (Rb) is a tumor suppressor that inhibits proliferation
through binding to and suppressing the activity of the E2F
family of transcription factors [5]. In early G1, when condi-
tions are favorable for proliferation, D-type cyclin levels
increase through transcriptional and posttranscriptional mech-
anisms [6]. Increased cyclin D drives the formation of active
kinase heterodimers with CDK4 and CDK6 (CDK4/6) cata-
lytic subunits. Active CDK4/6 then phosphorylates Rb, par-
tially relieving suppression of E2F to allow expression of
genes required for passage through the restriction point [7,
8]. This includes expression of cyclin E, which activates
another kinase (CDK2) leading to hyperphosphorylation of
Rb, fully releasing the suppression of E2F: allowing cells to
exit the G1 phase and initiate DNA replication. Additional
restriction point control occurs through the action of the
endogenous CDK inhibitors p16/ink4a and p21cip1; p16/
ink4a blocks the binding of D-type cyclins to CDK4/6;
CDK4/6 cyclin D complexes are stabilized by p21cip1, also
sequestering it and preventing the inhibition of CDK2/cyclin
E [4]. Phosphorylation of Rb by CDK4/6 also leads to tran-
scription of genes involved in cell cycle-independent activities
including signal transduction, DNA repair transcriptional con-
trol, and mRNA processing [9]. CDK4/6 have also recently
been shown to phosphorylate other proteins, including
FOXM1 and E2F1 [10, 11], which modulate additional cellu-
lar processes that are cell cycle -independent.
The central role of the Rb pathway in controlling cellular
proliferation is highlighted by its frequent dysregulation in
human cancer. Aberrant expression of D-type cyclins results
in activation of CDK4/6, allowing cells to circumvent the
restriction point. In mantle cell lymphoma (MCL), cyclin D1
is upregulated by the (11;14) chromosomal translocation seen
in this tumor, and cyclin D1 is overexpressed in many breast,
head and neck, prostate, and melanoma tumors [12, 13]. D-
type cyclins have also been shown to be downstream effectors
of Flt3 in acute myeloid leukemia (AML) [14]. CDK4 is
amplified or overexpressed in several tumors, including soft
tissue sarcomas, glioblastoma, and melanoma [15–18]. CDK6
has also been shown to be overexpressed in tumors [4]. Both
p16/ink4a and Rb act as tumor suppressors and are found to be
functionally inactivated in numerous tumor types [19, 20].
While CDK4/6 are considered highly validated targets for
therapeutic intervention, progress toward development of in-
hibitors for these kinases has been limited by issues with
potency, select ivi ty, and poor pharmacological /
physiochemical properties. Examples of these initial efforts
include flavopiridol, UCN-01, and CYC202 (roscovitine)
[21]. Fry et al. recently reported a CDK4/6 inhibitor, PD
0332991, possessing improved potency and selectivity over
previous inhibitors [22]. Here, we report the identification of
LY2835219, a potent inhibitor of CDK4/6 that inhibits phos-
phorylation of Rb and induces a G1 cell cycle arrest in Rb-
proficient tumor cells in vitro. In vivo, LY2835219 inhibits
phosphorylation of Rb by CDK4/6 causing a G1 arrest
resulting in antitumor activity in human tumor xenograft
models. Physiochemical and pharmacological properties of
the compound allow for oral administration, and no tumor
outgrowth or significant adverse activities were seen with
prolonged administration. When LY2835219 is used in com-
bination with gemcitabine, enhanced inhibition of tumor
growth is seen and is associated with a reduction of ribonu-
cleotide reductase (RR) expression without a significant inhi-
bition of Rb phosphorylation, suggesting a cell cycle indepen-








pyridinyl] amino] pyrido[2,3-d] pyrimidin-7 (8H)-one] and
gemcitabine [2′,2′-difluorodeoxycytidine hydrochloric salt]
were synthesized and characterized for purity and identity at
Lilly Research laboratories. Data for LY2835219 and
PD0332991 described herein were obtained using the
methanesulfonate salt of each compound.
Cell lines
All cell lines were obtained from American Type Culture
Collection and maintained using the recommended culture
conditions. Colo-205 was obtained in April 2005. MV-4-11
was obtained in August 2005. MDA-MB-231 was obtained in
February 2005. MDA-MB-468 was obtained in August 2008.
U2OS was obtained inMarch 2009. U-87MGwas obtained in
May 2004. NCI-H460 was obtained in February 2005. Calu-6
was obtained in February 2005 and Jeko-1 in November 2009.
MCF10A was obtained in September 2011. MDA-MB-361
was obtained in November 2013. Cell line authenticity was
confirmed by DNA fingerprinting (IDEXX RADIL).
Enzymatic profiling
Details for enzymatic assays are provided in the supplemen-
tary materials. Briefly, CDK4 and CDK6 activity was
826 Invest New Drugs (2014) 32:825–837
determined by radiometric-filter binding assay using a c-
terminus fragment of the human Rb protein (containing amino
acids 773 to 928, Millipore) as a substrate. Human
CDK4/cyclin D1 and CDK6/cyclin D1 complexes were
expressed in insect cells and purified as described
(ProQinase). Test compounds were serially diluted 1:3 in
20 % DMSO to create a 10-point curve at a starting concen-
tration of 20 μM. Twenty percent DMSO buffer alone without
test compound was employed as a control; 500 mM EDTA
was used to determine the level of background in the absence
of enzyme activity. A 4-parameter logistic curve fit is used to
generate the IC50 values using ActivityBase™ software
(IDBS). For kinetic analysis, a range of ATP concentrations
was used and Ki for both CDK4/cyclin D1 and CDK6/cyclin
D1 complexes was determined by fitting to the Michaelis-
Menten equation for a competitive inhibitor using GraphPad
Prism. Detailed methods are found in the supplemental
materials.
Cell assays
Details for the cellular assays are provided in the supplemental
materials. Briefly, image-based assays (Acumen Explorer,
TPP LabTech) were used for compound screening. Cells were
seeded in 96-well dishes, allowed to attach overnight and then
treated with test compounds for 24 h. After treatment, the cells
were washed, fixed and stained with antibodies to detect
phosphoproteins and Propidium Iodide to monitor DNA con-
tent. The plates were then analyzed on an Acumen Explorer
(TTP Labtech). The IC50 and EC50 values are determined by
curve fitting to a 4-parameter logistic for each output using
ACTIVITY BASE™ software.
Flow cytometry was also used to determine cell cycle
distribution in cell lines, as described in the supplemental
materials.
Western blot analysis
Cells or tissues were lysed in a buffer containing 1 % SDS in
water, protease (Roche Applied Science) and phosphatase
(Sigma Aldrich) inhibitors. Following lysis, the samples were
heated at 95 °C for 10 min, passed through a 25G needle to
shear genomic DNA, and briefly sonicated. Proteins (10–
20 μg per lane) were resolved SDS-PAGE on 4–20 % Tris-
glycine gels, transferred to nitrocellulose membranes and
blocked for 1 h at room temperature in 5 % dry milk in TBST
(137 mM sodium chloride, 20 mM Tris, 0.05 % Tween-20).
The membranes were then incubated overnight at 4 °C in
primary antibody diluted in 5 % BSA/TBST, a list of primary
antibodies used is provided in the supplemental materials.
Membranes were then washed in TBST, incubated 1 h at room
temperature with the appropriate horseradish peroxidase con-
jugated secondary antibody (Amersham ECL) in 3 %
milk/TBST, washed with TBST and developed using chemi-
luminescent substrate (SuperSignal Western, Pierce). Western
blot band intensity was determined using a BioRad VersaDoc
Molecular Imager with TotalLab software (BioSystematica).
The percent change in band intensity was calculated using
vehicle-treated sample bands as 100 %. One-way ANOVA
statistical analysis of the data was performed using JMP
software (SAS Institute).
Tumor xenograft studies
All animal studies were performed in accordance with Amer-
ican Association for Laboratory Animal Care institutional
guidelines, and all protocols were approved by the Eli Lilly
and Company Animal Care and Use Committee. Tumor cell
lines were grown, harvested, and resuspended in a 1:1 mixture
of serum-free media and matrigel (BD Biosciences), and 5×
106 cells were injected subcutaneously in the rear flank of 5-
to-6-week-old CD1 nu/nu female mice (Charles River Labo-
ratories for MV4-11, mice from Harlan Laboratories for
others). Tumor volume was estimated by using the formula:
vol=l × w2 × 0.536, where one and w are perpendicular
measured diameters, and one is greater than or equal to w.
When the mean tumor volume was approximately 150–
300 mm3, animals were randomized by tumor volume and the
compound was administered. LY2835219 was formulated in
1 % hydroxyethyl cellulose + 0.1 % antifoam in 25 mM PB
pH 2 and administered orally by gavage (final volume 0.2 mL)
at the indicated dose and schedule. Gemcitabine was formu-
lated in saline and administered by intraperitoneal injection.
Tumor volume and body weight were measured twice weekly.
When tumors were collected for biomarker analysis, the ani-
mals were asphyxiated with CO2 and the xenograft tumors
excised, flash frozen in liquid nitrogen, and stored at −80ºC
until analyzed. For analysis, tumor volume data were trans-
formed to a log scale to equalize variance across time and
treatment groups. The log volume data were analyzed with a
2-way repeated measures analysis of variance by time and
treatment using the MIXED procedure in SAS software (ver-
sion 9.2). The correlation model for the repeated measures
was spatial power. Treated groups are compared to the control
group at each time point.
Results
Identification of LY2835219
Compound screening identified the 2-Anilino-2,4-Pyrimi-
dine-[5-Benzimidazole] scaffold as potent inhibitors of
CDK4/cyclin D1 and CDK6/cyclin D1. The scaffold was
subsequently optimized through extensive structure–activity
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relationship studies with the aid of structure-based design, by
biochemical screening against a small panel of kinases to
improve potency and selectivity, and with a colo-205 cell high
content imaging assay monitoring inhibition of Rb phosphor-
ylation, cell cycle distribution, and cell number to assess
cellular inhibition of CDK4/6. Compounds with potent cellu-
lar activity were subsequently tested for cell cycle activity
with special focus in optimizing for G1 arrest in vitro and
in vivo (see discussion below), in vivo inhibition of Rb
phosphorylation and pharmacokinetic properties. Superior
compounds in terms of physicochemical and pharmacokinetic
properties were then tested for in vivo antitumor activity
against xenograft tumors in immunodeficient mice.
LY2835219 was selected for its potent biological activities
and optimal pharmacological properties within this chemical
series (Fig. 1a). All preclinical characterization was performed
with the methanesulfonate salt.
In biochemical assays, LY2835219 inhibits CDK4/cyclin
D1 and CDK6/cyclin D1 with IC50=2 nmol/L and
10 nmol/L, respectively, and shows selectivity over closely
related cell cycle kinases (Table 1). Precise Ki ATP con-
stants were determined through kinetic studies, showing
KiATP=0.6 nmol/L and 2.4 nmol/L for CDK4/cyclin D1
and CDK6/cyclin D1, respectively, indicating LY2835219
is a competitive ATP inhibitor. Kinase selectivity was
further evaluated in a panel of 100 protein kinases
(Millipore/UBI). Single point concentration assays were
followed by IC50 determination for the most active kinases
(Table 1). LY2835219 was also later profiled against 456
kinases (KINOMEscan, DiscoverRx) for single point bind-
ing at 200 nM and 2 μM concentrations (Fig. 1b). When
tested at approximately 200 fold concentration over the Ki
for CDK4, the observed binding profile was significantly
concentrated in the CGMC family of kinases that com-
prises cyclin-dependent kinases and MAPK kinases
(Fig. 1b, left panel), which is consistent with the IC50s
obtained from the original screening of 100 kinases. Out of
all these biochemical profiling activities, it is particularly
important to observe approximately 2–3 orders of magni-
tude in measured IC50s in biochemical kinase selectivity
against CDK1/cyclin B1, CDK2/cyclin E, and CDK7/Mat1/
cyclin H. Complete lack of activity against other important
cell-cycle related kinases for which inhibition could also
lead to potentially confounding cell cycle arrest in G2/M
such as Aurora A, B, and PLK1 was noted. Activity
against CDK9/cyclin T1 was seen (IC50=57 nmol/L); but
did not translate to significant cellular CDK9 activity (in-
hibition of RNA polymerase C-terminal domain [Ser2]
phosphorylation (pCTD) or a G2/M arrest in U2OS cells,
Figure S1 and Table S1, Supplemental materials), possibly
due to compensation by CDK7 [23]. Activity was also
seen against PIM1 (IC50=50 nmol/L) and to a lesser extent
against PIM2 (IC50=3.4 μmol/L, Table 1).
Cellular activity of LY2835219
Rb Phosphorylation by CDK4/6 is required for cells to pro-
ceed through the G1 restriction point [8]. Therefore, inhibition
of CDK4/6 will prevent Rb phosphorylation, arrest cells in
G1 at the restriction point, and inhibit proliferation. Several
complementary cellular assays were used to monitor Rb phos-
phorylation, cell cycle status, and proliferation. Cellular activ-
ity was assessed in tumor cell lines of different histologies, Rb
status and relevant oncogenic alterations (Supplemental
materials Table S2). Cellular inhibition of CDK4/6 was deter-
mined by monitoring Rb phosphorylation at serine 780 (p-
Rb), which is specific for CDK4/6 [24]. Cell cycle status was
monitored by measuring cellular DNA content and/or western
blot analysis for cell cycle-specific markers; proliferation was
assessed by changes in cell number. Unless otherwise noted,
all cell assays were performed with compound treatment for
24 h, approximately one cell cycle, to observe changes in cell
a b
200 nM   LY2835219 2 M   LY2835219
Fig. 1 a Structure of
LY2835219. b KINOMEscan
dendogram for biochemical
kinase selectivity profile against
456 kinases. single point binding
at 200 nM (left) and 2 μM (right)
LY2835219
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cycle distribution. Colo-205 colorectal cells treated with
LY2835219 showed a concentration-dependent inhibition of
p-Rb and a corresponding arrest of cells in G1 (2 N DNA
content), resulting in a decreased number of cells due to
inhibition of proliferation. The IC50 for p-Rb in colo-205 cells
was 120 nmol/L; the EC50 for accumulation of cells with 2 N
DNA content was 72 nmol/L (Fig. 2a). Inhibition of p-Rb and
the G1 arrest was maintained at compound concentrations up
to 6,000 nmol/L (approximately 50× the EC50 for p-Rb and
80× the EC50 for G1 arrest) consistent with no off-target cell-
cycle activity within that concentration range. Similar results
were observed for several breast cancer cell lines, as for
exampleMDA-MB-361 (Table 1) andMCF10A. InMCF10A
and after 24 h of compound incubation, consistent inhibition
of pRb and sustained G1 arrest was observed (Fig. 2a).
The ability of LY2835219 to inhibit p-Rb and induce a G1
arrest was also confirmed in MV4-11 AML cells. Maximum
G1 arrest was seen at concentrations ≥320 nmol/L (Fig. 2b).
Western blot analysis was performed using the three cell-
cycle-specific markers: p-Rb, a marker for CDK4/6 inhibition
and a phenotypic marker for cells in G1; topisomerase II alpha
(TopoIIα), a marker for cells in S phase [25]; and phospho-
histone H3 serine 10 (pHH3), a marker for cells in M phase
[26]. A sustained G1 arrest is indicated by strong inhibition of
all markers. LY2835219 inhibits all 3 markers, consistent with
cells arrested in G1 (Supplemental materials Figure S2). Inhi-
bition of PIM1 kinase was also observed in MV4-11 cells as
indicated by a dose-dependent inhibition of phosphorylation
of several PIM substrates including pBAD (Ser112) and 4E-
BP1 (Thr37/46) (Supplemental materials Figure S3). Similar
to colo-205 andMCF10A cells, the G1 arrest in MV4-11 cells
was sustained at high compound concentrations (up to
5,000 nmol/L).
Functional Rb protein is required for CDK4/6 to regulate
the G1 restriction point; the mechanism of action for
LY2835219 was further defined in breast cancer cell lines
with and without functional Rb [27]. LY2835219 induced a
G1 arrest in Rb-proficient MDA-MB-231 breast cancer cells,
whereas no such effect was seen in Rb-deficient MDA-MB-
468 breast cancer cells at compound concentrations up to
2,500 nmol/L (Fig. 2c). The data are consistent with
CDK4/6 inhibition and with the hypothesis that G1 arrest
induced by LY2835219 requires functional Rb.
LY2835219 inhibits Rb phosphorylation by CDK4/6 causing
a sustained G1 arrest in vivo
Pharmacokinetic and pharmacodynamic properties of
LY2835219 were assessed in mice bearing colo-205 human
xenografts 24 h after oral dosing to allow for the observation
of cell cycle effects. In vivo inhibition of p-Rb was dose-
dependent and correlated well with inhibition of TopoIIα
and pHH3 with all three markers significantly inhibited at
Table 1 LY2835219 biochemical and cellular profiling
LY2835219
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Cellular profiling IC50 (nmol/L)d
pRb inh. (pSer780) colo-205 120±36 (n=6)
G1 arrest colo-205 72±31 (n=7, EC50)
pRb inh. (pSer780) MDA-MB-361 60±40 (n=3)e
G1 arrest MDA-MB-361 20±13 (n=3, EC50)
e
Cell viability MDA-MB-361 90±31 (n=3)e
pCTD inh. (pSer2) U2OS 3510±1560 (n=4)
pHH1 inh. Calu6 17400±4000 (n=4)
pERK inh. HCT116 >20000 (n=2)
pERK inh. A375 >20000 (n=2)
(a) unless otherwise indicated, all data was generated internally at Eli
Lilly and company. All human kinases. (b) for n>1, average of indepen-
dent determinations±standard deviation. (c) IC50 generated at millipore
(UBI) kinase panel for kinases >90 % inhibition at 200 nM concentration
of inhibitor. (d) geometric mean for n>1 determinations±standard devi-
ation. (e) determined after 6 days of incubation due to long doubling times
for MDA-MB-361
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doses of 12.5 mg/kg and higher (Fig. 3a). Time course studies
showed maximum inhibition occurred 24 h after administra-
tion (Fig. 3b). The cell cycle arrest was reversible, with cells
released back into the cell cycle in a sequence predicted by a
G1 arrest. Thirty-six hours after dosing, inhibition of CDK4/6
was released and levels of p-Rb returned to baseline as Rbwas
again phosphorylated by CDK4/6. TopoIIα levels also in-
creased as cells cycled into S phase, but pHH3 remained
inhibited as cells released from G1 had not yet reached M
phase. By 48 h, pHH3 returned to baseline, consistent with
cells enteringM phase; levels of p-Rb and TopoIIα rebounded
above baseline, indicating a partial synchronization of tumor
cells. Pharmacokinetic analysis showed plasma levels of
LY2835219 peaked before inhibition of all markers, indicat-
ing the cell-cycle arrest can occur after maximal plasma ex-
posure (Fig. 3b).
In addition to the cell cycle markers, we assessed the
modulation of several Rb/E2F-regulated proteins that are the
targets of cytotoxic drugs [28]. In colo-205 cells, DHFR,
RRM1 and RRM2 were shown to be inhibited in a dose-
and time-dependent manner similar to the cell cycle markers
(Fig. 3a, b).
In vivo antitumor activity of LY2835219 alone
and in combination with gemcitabine
In vivo antitumor activity of LY2835219 was assessed in
subcutaneous human tumor xenografts. LY2835219 signifi-
cantly inhibited the growth of colo-205 xenografts; doses up
to 100 mg/kg were well tolerated with no loss of body weight
or other signs of toxicity during or after treatment (Fig. 4a).
The inhibition of tumor growth at the end of treatment was
dose-dependent from 25 to 100mg/kg doses (Fig. 4a, Table 2).
Tumors from additional animals treated with 100 mg/kg
LY2835219 for 21 days were harvested and cell cycle status
determined by western blot; significant inhibition of p-Rb,
TopoIIα and pHH3 was seen (Fig. 4b). This was consistent
with the antitumor activity of LY2835219, attributable to
inhibition of Rb phosphorylation by CDK4/6, resulting in a
G1 cell cycle arrest. Antitumor activity was seen in other
a
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Fig. 2 a Activity of LY2835219 in colo-205 and MCF10A cells using a
multiplexed assay measuring p-Rb serine 780 (green), cells in G1 (2 N
DNA content, red) and total cell number (black). after 24-hour exposure
LY2835219 shows a dose-dependent inhibition of p-Rb (ser780) and a
corresponding sustained G1 arrest. bMV4-11 acute myelocytic leukemia
(AML) cells treated with increasing concentrations of LY2835219 for
24 h and cell cycle activity profiled by flow cytometry. c cell cycle
activity of LY2835219 in cells with and without functional Rb.
LY2835219 gives a G1 cell cycle arrest in Rb-proficient MDA-MB-231
breast cancer cells, but not in Rb-deficient MDA-MB-468 breast cancer
cells
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xenograft tumors of different histologies including MV4-11
AML,U87MGglioblastoma, andH460 lung (Fig. 4c, Table 2,
see also Table S2 Supplemental materials). LY2835219 also
inhibited colo-205 tumor growth at a dose of 12.5 mg/kg
every day, which corresponds with the minimum dose re-
quired to inhibit the cell cycle markers, and when adminis-
tered every other day at 50 mg/kg (Table 2). The antitumor
activity of LY2835219 was similar to another CDK4/6 inhib-
itor in these subcutaneous xenografts (PD0332991, Fig. 4a–c,
Table 2); further indicating LY2835219 is specifically
inhibiting CDK4/6.
To assess the long-term antitumor activity and safety of
LY2835219, colo-205 xenograft-bearing mice were treated
for 56 days with continuous and intermittent dosing schedules
(56 days continuously or 2 cycles of 3 weeks on/1 week rest,
Fig. 4d). Both schedules produced a similar robust inhibition
of tumor growth and were well tolerated with no loss of body
weight. Hematologic and histopathologic evaluations from
treated animals on days 41 and 69 showed no significant
changes in intestinal tissue (jejunum, ileum, cecum). Some
hematologic changes were observed on both schedules (in-
cluding decreases in red cell mass and moderately reduced
lymphocyte count) but were not dose-limiting. Acquired drug
resistance can occur due to prolonged treatment with kinase
inhibitors [29]. No tumor outgrowth was seen with prolonged
treatment of colo-205with extended dosing on either schedule
(Fig. 4d), indicating acquired resistance did not develop over
the period of treatment.
Cytotoxic drugs are commonly used to treat cancer; com-
bining CDK4/6 inhibitors with cytotoxic drugs may increase
their clinical effectiveness. Previous studies suggested some
CDK inhibitors may antagonize cytotoxic efficacy when com-
bined with cytotoxic drugs; therefore, require sequential ad-
ministration [30]. We evaluated sequential and combination
dosing of LY2835219 and the cytotoxic drug gemcitabine, an
inhibitor of DNA synthesis approved for the treatment of
several cancers, including pancreatic, metastatic breast, ovar-
ian and non-small cell lung cancer. Calu-6 lung tumor xeno-
grafts were used as their response to gemcitabine has been
previously characterized [31]. Individual doses of 50 mg/kg
LY2835219, 60 or 150 mg/kg gemcitabine, a sequence of
LY2835219 followed by gemcitabine or the 2 compounds
together were given. Both LY2835219 and gemcitabine alone
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Fig. 3 In vivo target inhibition by
LY2835219. a tumors harvested
24 h after dosing for analysis with
the markers topoIIα (S phase-
specific), p-Rb (pRb ser 780, G1-
specific), pHH3 (M-specific), and
the Rb/E2F regulated proteins
DHFR, RRM1 and RRM2.
GAPDH was used as a loading
control. statistical significance
(p <0.05) is indicated above each
dose by an asterisk for pRb,
Topollα, and pHH3, respectively.
b time course of LY2835219.
tumor-bearing animals were
dosed orally with 50 mg/kg of
LY2835219 and tumors harvested
at the indicated times (n=5 per
treatment, n=8 for vehicle). the
percent change in band intensity
was calculated using vehicle-
treated bands as 100 %. mean
(±SD) plasma concentrations of
the compound are shown in the
lower right panel
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a greater inhibition of tumor growth than either treatment
alone (Fig. 5a). The sequenced group was also active, al-
though not significantly different from the individual com-
pounds, or the 150 mg/kg gemcitabine group. Together, the
sequence and combination treatments indicate there was no
antagonism. Comparison of changes in body weight for all
groups (including vehicle) showed a transient weight loss
upon initiation of dosing, followed by recovery to baseline,
indicating no significant toxicity when LY2835219 and
gemcitabine were administered together. Based on the avail-
able exposure data, there is no evidence of drug-drug interac-
tion for any of the two agents used in this combination study.
The mechanism of action for the antitumor activity of
LY2835219 and gemcitabine was further analyzed by western
blot analysis in tumors collected 24 h after the last dose. No
significant changes were found for p-Rb, TopoIIα, or pHH3
except for an increase in TopoIIα in the sequence group
(Fig. 5b). These results indicate a cell cycle arrest did not
result from the treatments; the increase in TopoIIα seen for the
sequenced treatment may indicate a partial cell cycle synchro-
nization by LY2835219, resulting in an increase of cells in S
phase. Expression of RRM1 and RRM2 was also analyzed. A
significant increase of RRM1 was seen with the 150 mg/kg
gemcitabine dose (75 % compared to vehicle), possibly due to
cellular compensation resulting by its inhibition by
gemcitabine. A significant inhibition (approximately 40 %)
was seen for both the sequence and combination treatments,
suggesting that inhibition of RRM1 expression by
LY2835219 may be sensitizing tumor cells to the activity of
gemcitabine.
Discussion
The Rb pathway is dysregulated in more than 80 % of human
cancers, highlighting its critical role in controlling cellular
























































































Fig. 4 In vivo antitumor activity of LY2835219 in subcutaneous human
tumor xenografts. Tumors were implanted in the rear flank of athymic
mice and randomized for treatment when the mean tumor volume reached
150 to 200 mm3. LY2835219 and PD0332991 were administered at the
indicated dose and schedule. treatment period is indicated by the hori-
zontal black bar along the X-axis, body weight shown for each experi-
ment is shown in the upper left corner. a effect of 25, 50, or 100 mg/kg of
LY2835219 and 100 mg/kg PD0332991 on colo-205 xenografts. b
inhibition of cell cycle markers in colo-205 xenografts at the end of
treatment with 100 mg/kg LY2835219. c effect of 25, 50, or 100 mg/kg
LY2835219 and 50 mg/kg PD0332991 in MV4-11 xenografts. d
LY2835219 inhibits tumor growth and is well tolerated in mice bearing
colo-205 xenografts when dosed 56 days with 50 mg/kg continuously or
intermittently
832 Invest New Drugs (2014) 32:825–837
include overexpression of D-type cyclins, activating muta-
tions and amplification of CDK4, and Rb and p16/ink4a
inactivation by deletion, mutation, or epigenetic silencing.
Data for the role of the Rb pathway in primary human tumors
are supported by extensive functional analysis in genetically
engineered mouse models [32]. The importance of the path-
way in tumorigenesis and recent success developing small
molecule kinase inhibitors, make CDK4/6 a highly validated
cancer drug target [33, 34]. Until recently, CDK inhibitors
have shown limited activity in clinical trials because of issues
with potency, selectivity and poor pharmacological/
physiochemical properties. CDK4/6 inhibitors with improved
pharmacokinetic and pharmacodynamic properties have re-
cently been described and are now entering advance stages of
clinical development. These recent results support the clinical
potential for selective targeting of CDK4/6 in the treatment of
cancer [35].
We describe the identification and preclinical characteriza-
tion of LY2835219, a potent inhibitor of CDK4/6 with
antiproliferative activity in a variety of tumor models in vitro
and in vivo. In addition to monitoring p-Rb, we phenotypi-
cally assessed the cell cycle status in cellular and in vivo
assays; as we previously showed p-Rb alone was not consid-
ered sufficient to determine cell cycle activity [36]. In vitro
LY2835219 inhibits Rb phosphorylation by CDK4/6,
resulting in a sustained G1 arrest at concentrations 50-fold
greater than the cellular IC50 for p-Rb inhibition, indicating no
off-target activity. Consistent with the cell cycle mechanism of
action of LY2835219, cell cycle arrest occurred only in Rb-
proficient cells. Cell cycle activity was further tested in vivo
by monitoring markers for specific cell cycle compartments.
LY2835219 effectively inhibited phosphorylation of Rb at
serine 780, and significant inhibition of all markers was
achieved in colo-205 xenografts at doses of 12.5 mg/kg and
higher, indicating a block at the G1 restriction point
preventing cells from cycling into the S and M compartments
(monitored by TopoIIα and pHH3, respectively). Maximum
inhibition of p-Rb and the cell cycle occurred 24 h after
Table 2 Antitumor activity of LY2835219 in subcutaneous human tumor xenografts
Xenograft model Compound dose Percent delta T/C,
percent regression
P-Value Day calculated
Colo-205 colorectal 100 mg/kg qdx21 0 <0.001 day 35
50 mg/kg qdx21 28 <0.001 day 35
25 mg/kg qdx21 52 <0.001 day 35
PD0332991, 100 mg/kg qdx21 −1 <0.001 day 35
MV4-11 AML 100 mg/kg qdx21 −48 <0.001 day 49
50 mg/kg qdx21 30 <0.001 day 49
25 mg/kg qdx21 45 0.008 day 49
PD0332991, 50 mg/kg qdx21 16 <0.001 day 49
U87 MG glioblastoma 100 mg/kg qdx21 1 <0.001 day 31
50 mg/kg qdx21 33 <0.001 day 31
25 mg/kg qdx21 49 0.001 day 31
PD0332991, 50 mg/kg qdx21 26 <0.001 day 31
H460 lung 100 mg/kg qdx21 36 <0.001 day 35
50 mg/kg qdx21 60 <0.001 day 35
25 mg/kg qdx21 84 NS day 35
PD0332991, 50 mg/kg qdx21 60 <0.001 day 35
Colo-205 colorectal 12.5 mg/kg qd 53 0.087 day 39
50 mg/kg q2d 27 0.003 day 39
50 mg/kg qd 0 <0.001 day 39
PD0332991, 50 mg/kg 7 <0.001 day 39
Calu-6 lung 50 mg/kg, qdx10 42 0.007 day 20
50 mg/kg, qdx22 48 <0.001 day 34
Jeko1 MCL 100 mg/kg 10 <0.001 day 45
PD0332991, 100 mg/kg 12 <0.001 day 45
100 % if treated volume = control volume
0 % if treated volume = baseline volume
−100 % if treated volume = zero
with linear interpolation between these points
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LY2835219 administration and was sustained after maximal
plasma exposure (Fig. 3). Release from the G1 block was seen
through the temporal repopulation of S and M phases, indi-
cated by the sequential loss of p-Rb inhibition (indicating
active CDK4/6, and cells entering late G1 phase) followed
by TopoIIα (S phase), and finally pHH3 (M phase). In colo-
205 xenograft dose response target inhibition studies the
TED70 for LY2835219 is 14 mg/kg for in vivo inhibition of
both pRb and TopoII (Fig. 3a). This value is in agreement with
the observed minimally efficacious dose of 12.5 mg/kg for
tumor growth inhibition. Due to the cell cycle-dependent
nature of the PD effect and the observed indirect PK/PD
relationship in mouse models, plasma concentrations do not
directly correlate with in vivo target inhibition in xenografts,
as maximal target inhibition is observed at 24 h post-acute oral
dose (Fig. 3b). An integrated and semi-mechanistic
pharmacokinetics/pharmacodynamics (PK/PD) model was
developed to describe the indirect PK/PD relationship be-
tween LY2835219 plasma concentration, inhibition of pRb
and subsequent cell cycle arrest, and in vivo efficacy in colo-
205 bearing mice [37]. This PK/PD analysis concludes that
sustained, continuous in vivo pRb inhibition and cell cycle
arrest are required for robust efficacy in colo-205, and sup-
ports a continuous dosing strategy achieving minimum steady
state trough plasma concentrations of approximately 200 ng/
mL (approximately 400 nM). In this context, it is important to
note that the desired cell cycle phenotype in preclinical models
in vitro (Fig. 2) and in vivo (Fig. 3) is retained when
LY2835219 is dosed up to single digit micromolar concentra-
tions (Fig. 3b). In a phase 1 study in advanced cancer patients,
pharmacodynamic activity as well as clinical efficacy were
observed. Plasma concentrations in this study reached a mean
maximum steady state value of 562 nM [38, 39], consistent
with the target plasma concentrations from our PK/PD model.
In total, these data suggest that, in vivo, LY2835219 inhibits
CDK4/6 at plasma concentrations clinically achievable,
resulting in a G1 arrest that can be sustained with continuous
oral dosing.
CDK4 and CDK6 are functionally redundant and ubiqui-


























































































































































































Fig. 5 In vivo antitumor activity
of LY2835219 and gemcitabine. a
Calu-6 lung xenografts were




gemcitabine, or both compounds
together. treatment period is
indicated by horizontal black bar
along the X-axis and body weight
is shown in the upper left corner.
b results of target inhibition
studies
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proliferation of tumors arising from different cellular origins.
LY2835219 is a potent inhibitor of both CDK4 and CDK6
kinases with potent cellular inhibition of pRb (Fig. 2a) of
approximately 100 nM and has good selectivity over other
closely related kinases (approximately 1000-fold selective for
CDK1 and≥100-fold selective for CDK2 and CDK5). Bio-
chemical kinase profiling is best interpreted in the context of
the functional cellular potency and selectivity for a given drug
candidate (see Table 1 for cellular profiling). Factors to con-
sider are the expected potency shift due to the higher intracel-
lular ATP concentration and Km, conformational differences
in the native state of protein kinases with respect to conditions
and constructs used for biochemical assays, and compensation
by other kinases not seen in biochemical assays. For
LY2835219 among other kinases in the CMGC kinome fam-
ily, some activity below 100 nM was observed against CDK9
and PIM1 kinases in biochemical assays. However, the inhi-
bition of CDK9 seen in biochemical assays did not translate
into cellular CDK9 activity (inhibition of pCTD and a G2/M
arrest in U2OS cells, Figure S1). Similarly, while activity
against PIM1 was seen in biochemical assays, monitoring of
the cell cycle in vitro and in vivo shows LY2835219 induces a
G1 cell-cycle arrest, even in MV4-11 and Jeko-1 cells and
xenografts, which express high levels of PIM1 [40–43]. In
MV4-11 cells and unlike PD0332991, LY2835219 showed
significant inhibition of pBAD (Ser112), and p4E-BP1 (Thr37
and 46), known substrates of PIM kinases, at concentrations
equal or higher than 625 nM after 24 h of incubation
(Figure S3). Both compounds showed similar potent inhibi-
tion of pRb (Ser780) in MV4-11. Although the presence of
functional cellular PIM1 activity for LY2835219 in these
hematological tumor types that are presumably sensitive to
PIM inhibition seems possible, the very similar MV4-11 and
Jeko-1 xenograft efficacy observed for this molecule with
respect to another CDK4/6 inhibitor without PIM1 activity
(Fig. 4c, Table 2) suggests a modest effect of this activity
compared to CDK4/6 for this particular tumor type, possibly
due to compensation by PIM2 or other kinases. More work is
be needed to further elucidate the potential role of this PIM1
activity in other tumor types. Overall, these results demon-
strate that, in MV4-11, inhibition of PIM1 does not abrogate
G1 cell-cycle arrest that arises from the inhibition of CDK4/6.
In vivo target inhibition studies showed LY2835219 pro-
duced a cell cycle arrest 24 h after dosing, and was reversible
(Fig. 3). The arrest was maintained even after peak plasma
concentrations were achieved and indicates target inhibition
and antitumor activity can be maintained with daily dosing
schedules. This was confirmed in efficacy studies. Significant
antitumor activity was seen when LY2835219 was adminis-
tered orally in several different human tumor xenografts. In
colo-205, doses of 12.5 mg/kg and higher inhibited tumor
growth and were associated with inhibition of p-Rb, TopoIIα,
and pHH3. This shows in vivo antitumor activity results from
inhibition of CDK4/6 resulting in a G1 arrest. The antitumor
activity of LY2835219 was confirmed in several additional
human xenografts representing different human histologies,
and was dose-dependent. LY2835219 antitumor activity was
further confirmed by comparison of in vivo efficacy to another
CDK4/6 inhibitor, PD0332991 (which has similar activity
against CDK4/6). In all models tested, both compounds gave
similar antitumor activity at similar doses (Fig. 4, Table 2).
Finally, antitumor activity of LY2835219 was sustained for up
to 56 days with continuous or intermittent dosing schedules in
mice bearing colo-205 xenografts without significant adverse
events or evidence of acquired resistance (Fig. 4d).
LY2835219 can be combined with the cytotoxic drug
gemcitabine, approved to treat several types of tumors, includ-
ing lung cancer [44]. In calu 6 lung xenografts both
LY2835219 and gemcitabine alone were active in inhibiting
tumor growth. Administering the compounds together or in
sequence had greater antitumor activity than the individual
treatments and was equivalent to the maximum tolerated dose
of gemcitabine (150 mg/kg) [31]. Contrary to other xenograft
models, neither inhibition of p-Rb nor a cell cycle arrest was
associated with the antitumor activity of LY2835219 in calu-
6. However, a significant inhibition of RRM1 was seen when
LY2835219 was combined with gemcitabine. In vitro and
in vivo chemosensitivity to gemcitabine strongly correlates
to RRM1 expression [45, 46], consistent with the modulation
of RRM1 seen for LY2835219 and gemcitabine in our exper-
iments. CDK4/6 can phosphorylate substrates other than Rb,
such as FOXM1 and E2F1 [10, 11], which may explain the
inhibition of RRM1 and the absence of inhibition of p-Rb and
a cell cycle arrest. Alternatively, LY2835219 in calu-6 cells
may result in a low level of p-Rb inhibition not detected by
western blot or leading to a cell cycle arrest, but is sufficient to
inhibit the expression of RRM1. Consistent with the inhibition
of RRM1 in our experiments, expression of RRM1 was pre-
viously reported to be highly sensitive to regulation by p-Rb
[28]. Previously reported data that PD0332991 has efficacy
in vivo without inhibition of p-Rb [47] also suggest low levels
of inhibition of p-Rb may lead to antitumor activity
in vivo. Significantly, H460 contains activating KRAS
mutation in codon 61, like calu-6, and shows an attenuat-
ed response to LY2835219 (25 mg/kg dose Table 2),
consistent with a role for KRAS modifying response to
CDK4/6 inhibitors [48, 49].
In conclusion, we describe the identification and character-
ization of LY2835219, a potent inhibitor of CDK4/6. Broad
antitumor activity was observed in human xenograft tumors of
diverse histologic origin that represent human cancers with
alterations in the Rb pathway, including MCL, colorectal,
lung, glioblastoma and AML. The antitumor activity results
predominantly from a G1 cell cycle arrest that correlates with
inhibition of p-Rb. In calu-6 lung xenograft tumors,
LY2835219 can be combined with gemcitabine resulting in
Invest New Drugs (2014) 32:825–837 835
additive antitumor activity and inhibition of RRM1 in the
absence of a cell cycle arrest. These results indicate that the
antitumor activity of CDK4/6 inhibitors can be context-
sensitive, as previously reported in genetically engineered
mouse models for glioma and lung cancer [47, 48]. In addition
to its broad antitumor activity, LY2835219 has several addi-
tional desirable properties. Efficacy is correlated with tumor
Rb status and in vivo target inhibition, allowing for the devel-
opment of biomarkers for patient stratification and to monitor
drug response. A unique feature of LY2835219 is its ability to
effectively cross the blood–brain barrier; it has been shown to
be active in orthotopic brain tumor xenografts alone or in
combination with temozolomide (manuscript in preparation).
The Rb pathway is dysregulated in approximately 78 % of
glioblastoma and in tumors that commonly metastasize to the
brain such as breast, lung, and melanoma [49, 50]. These
properties support further clinical study of LY2835219 in the
treatment of both brain metastases and tumors arising in the
central nervous system [51–53]. LY2835219, is currently in
clinical trials (ClinicalTrials.gov identifiers: NCT01394016,
NCT01739309 , NCT02079636 , NCT02057133 ,
NCT02117648, NCT02014129).
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